ZA200604645B - Azabicyclic heterocycles as cannabinoid receptor modulators - Google Patents

Azabicyclic heterocycles as cannabinoid receptor modulators

Info

Publication number: ZA200604645B
Authority: ZA; South Africa
Prior art keywords: receptor modulators; cannabinoid receptor; azabicyclic; heterocycles; azabicyclic heterocycles
Prior art date: 2003-12-19

Application number

ZA200604645A

Other languages

English (en)

Inventor

Gu Guixue

Amarendra B Mikkilineni

Bruce A Ellsworth

Gerritz Samuel

Murugesan Natesan

William R Ewing

Pendri Annapurna

Philip M Sher

Sun Chongqing

Wu Ximao

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-19

Filing date

2006-06-06

Publication date

2007-11-28

2006-06-06 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2007-11-28 Publication of ZA200604645B publication Critical patent/ZA200604645B/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Reproductive Health (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Anesthesiology (AREA)
Child & Adolescent Psychology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)

ZA200604645A 2003-12-19 2006-06-06 Azabicyclic heterocycles as cannabinoid receptor modulators ZA200604645B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US53145103P	2003-12-19	2003-12-19

Publications (1)

Publication Number	Publication Date
ZA200604645B true ZA200604645B (en)	2007-11-28

Family

ID=34710226

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
ZA200604645A ZA200604645B (en)	2003-12-19	2006-06-06	Azabicyclic heterocycles as cannabinoid receptor modulators
ZA200604778A ZA200604778B (en)	2003-12-19	2006-06-09	Azabicyclic heterocycles as cannabinoid receptor modulators

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
ZA200604778A ZA200604778B (en)	2003-12-19	2006-06-09	Azabicyclic heterocycles as cannabinoid receptor modulators

Country Status (11)

Country	Link
US (1)	US7037910B2 (es)
EP (1)	EP1699796A4 (es)
JP (1)	JP2007514756A (es)
CN (2)	CN1918164A (es)
AR (2)	AR047063A1 (es)
IS (1)	IS8501A (es)
NO (1)	NO20062689L (es)
PE (2)	PE20050756A1 (es)
TW (2)	TW200528455A (es)
WO (1)	WO2005061509A1 (es)
ZA (2)	ZA200604645B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100210590A1 (en) *	1995-09-27	2010-08-19	Northwestern University	Compositions and treatments for seizure-related disorders
US20030176437A1 (en)	2001-08-31	2003-09-18	D.M. Watterson	Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death
RU2006126123A (ru)	2003-12-19	2008-01-27	Бристол-Маерс Сквибб Компани (Us)	Азабициклические гетероциклы как модуляторы каннабиоидного рецептора
US20060025448A1 (en) *	2004-07-22	2006-02-02	Cadila Healthcare Limited	Hair growth stimulators
WO2006050359A2 (en) *	2004-11-02	2006-05-11	Northwestern University	Pyridazine compounds and methods
CA2589106C (en)	2004-11-02	2015-07-21	Northwestern University	Pyridazine compounds, compositions and methods and their use in treating inflammatory diseases
US7317012B2 (en) *	2005-06-17	2008-01-08	Bristol-Myers Squibb Company	Bicyclic heterocycles as cannabinoind-1 receptor modulators
BRPI0710107A2 (pt) *	2006-03-30	2011-08-02	Irm Llc	composto, composição compreendendo o mesmo, bem como uso do mesmo
CA2650711A1 (en) *	2006-04-28	2007-11-08	Northwestern University	Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
AU2007243280A1 (en)	2006-04-28	2007-11-08	Northwestern University	Formulations containing pyridazine compounds for treating neuroinflammatory diseases
ATE448778T1 (de) *	2006-05-04	2009-12-15	Solvay Pharm Bv	Muscarin-agonisten zur behandlung von impulskontrollstörungen
AU2007283113A1 (en)	2006-08-08	2008-02-14	Sanofi-Aventis	Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
US20160331729A9 (en) *	2007-04-11	2016-11-17	Omeros Corporation	Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en)	2007-04-11	2022-02-08	Omeros Corporation	Compositions and methods for prophylaxis and treatment of addictions
ES2586433T3 (es) *	2007-04-11	2016-10-14	Omeros Corporation	Composiciones y métodos para la profilaxis y el tratamiento de adicciones
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009137335A1 (en) *	2008-05-05	2009-11-12	The Scripps Research Institute	Synthesis of (+) corstistatin a and related compounds
UY31968A (es)	2008-07-09	2010-01-29	Sanofi Aventis	Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en)	2008-12-08	2010-06-17	Sanofi-Aventis	A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
BR112012003973A2 (pt)	2009-08-26	2015-09-08	Sanofi Sa	hidratos de fluoroglicosídeo heteroaromático cristalinos, produtos farmacêuticos compreendendo estes compostos e seu uso
FR2958850B1 (fr) *	2010-04-14	2012-07-06	Centre Nat Rech Scient	Medicaments pour la prevention ou le traitement des addictions aux drogues
US8765820B2 (en) *	2010-04-20	2014-07-01	Universita Degli Studi Di Roma “La Sapienza”	Tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and/or LSD2
US8933024B2 (en)	2010-06-18	2015-01-13	Sanofi	Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8710050B2 (en)	2011-03-08	2014-04-29	Sanofi	Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120053A1 (de)	2011-03-08	2012-09-13	Sanofi	Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120050A1 (de)	2011-03-08	2012-09-13	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de)	2011-03-08	2012-09-13	Sanofi	Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de)	2011-03-08	2015-04-22	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809325B2 (en)	2011-03-08	2014-08-19	Sanofi	Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
EP2683701B1 (de)	2011-03-08	2014-12-24	Sanofi	Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8895547B2 (en)	2011-03-08	2014-11-25	Sanofi	Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
JP5437525B1 (ja)	2012-12-28	2014-03-12	株式会社ナード研究所	チロシン誘導体およびチロシン誘導体の製造方法
CN103933569B (zh) *	2013-01-22	2017-01-11	复旦大学	一种抗肺癌药物组合物及其应用、药盒和包装件
RS57533B1 (sr) *	2014-01-29	2018-10-31	Ucb Biopharma Sprl	Heteroaril amidi kao inhibitori proteinske agregacije
KR102478186B1 (ko) *	2016-06-03	2022-12-15	더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕	프라더-윌리 증후군을 치료하는 방법
CN108178759B (zh) *	2018-01-05	2020-06-09	上海瑞纷医药科技有限责任公司	一种α-肾上腺素受体拮抗剂的合成方法
CN108498511A (zh) *	2018-04-21	2018-09-07	徐晶	一种治疗膝关节骨性关节炎的药物组合物及其制备方法
WO2020087031A1 (en)	2018-10-26	2020-04-30	The Research Foundation For The State University Of New York	Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1164198B (it)	1983-04-28	1987-04-08	Isf Spa	Preparazione di un derivato piridazinico farmacologicamente attivo
AU6003099A (en)	1998-10-06	2000-04-26	Takeda Chemical Industries Ltd.	Fused pyridazine compounds, process for the preparation of the same and uses thereof
JP2002205992A (ja)	2000-11-08	2002-07-23	Takeda Chem Ind Ltd	二環式トリアゾロン誘導体およびそれを含有する除草剤
GB0107751D0 (en) *	2001-03-28	2001-05-16	Pfizer Ltd	Pharmaceutically active compounds
WO2003066061A1 (en) *	2002-02-07	2003-08-14	Pfizer Limited	Use of pde5 inhibitors such as sildenafil in the treatment of polycystic ovary syndrome
US7307164B2 (en) *	2002-03-25	2007-12-11	Merck & Co., Inc.	β-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CA2508731A1 (en)	2003-02-19	2004-09-02	Neurogen Corporation	Aryl acid pyrimidinyl methyl amides, pyridazinyl methyl amides and related compounds

2004
- 2004-12-15 TW TW093138982A patent/TW200528455A/zh unknown
- 2004-12-15 TW TW093138971A patent/TW200530246A/zh unknown
- 2004-12-17 CN CNA2004800419043A patent/CN1918164A/zh active Pending
- 2004-12-17 US US11/015,876 patent/US7037910B2/en not_active Expired - Lifetime
- 2004-12-17 AR ARP040104772A patent/AR047063A1/es not_active Application Discontinuation
- 2004-12-17 AR ARP040104771A patent/AR046964A1/es not_active Application Discontinuation
- 2004-12-17 CN CNA2004800419202A patent/CN1918165A/zh active Pending
- 2004-12-20 JP JP2006545502A patent/JP2007514756A/ja active Pending
- 2004-12-20 EP EP04814691A patent/EP1699796A4/en not_active Withdrawn
- 2004-12-20 WO PCT/US2004/042542 patent/WO2005061509A1/en not_active Ceased
2005
- 2005-01-03 PE PE2005000014A patent/PE20050756A1/es not_active Application Discontinuation
- 2005-01-03 PE PE2005000013A patent/PE20051047A1/es not_active Application Discontinuation
2006
- 2006-06-06 ZA ZA200604645A patent/ZA200604645B/xx unknown
- 2006-06-08 IS IS8501A patent/IS8501A/xx unknown
- 2006-06-09 ZA ZA200604778A patent/ZA200604778B/xx unknown
- 2006-06-12 NO NO20062689A patent/NO20062689L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CN1918165A (zh)	2007-02-21
NO20062689L (no)	2006-09-12
PE20050756A1 (es)	2005-10-06
US7037910B2 (en)	2006-05-02
ZA200604778B (en)	2007-12-27
AR046964A1 (es)	2006-01-04
PE20051047A1 (es)	2005-12-16
AR047063A1 (es)	2006-01-04
JP2007514756A (ja)	2007-06-07
EP1699796A1 (en)	2006-09-13
TW200530246A (en)	2005-09-16
US20050192278A1 (en)	2005-09-01
WO2005061509A1 (en)	2005-07-07
EP1699796A4 (en)	2009-03-04
TW200528455A (en)	2005-09-01
CN1918164A (zh)	2007-02-21
IS8501A (is)	2006-06-08

Publication	Publication Date	Title
ZA200604645B (en)	2007-11-28	Azabicyclic heterocycles as cannabinoid receptor modulators
EP1644370A4 (en)	2008-06-04	TETRAHYDROCHINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS
AP1828A (en)	2008-02-13	Muscarinic Acetycholine receptor antagonists
EP1670460A4 (en)	2008-09-03	PYRAZOLE DERIVATIVES AS MODULATORS OF THE CANNABINOID RECEPTOR
GB0400440D0 (en)	2004-02-11	Receptor modulators
AU2003209388A1 (en)	2003-09-02	Substituted imidazoles as cannabinoid receptor modulators
IL177218A0 (en)	2006-12-10	3-substituted 1,5-diphenylpyrazole derivatives useful as cb1 modulators
PL2653465T3 (pl)	2017-01-31	Modulatory receptora opioidowego
IL178290A0 (en)	2006-12-31	Tetrahydro-indazole cannabinoid modulators
IL172577A0 (en)	2006-04-10	Cannabinoid receptor modulator
EP1487798A4 (en)	2005-07-13	Substituted tetrahydroisoquinolines as C5A receptor modulators
IL176215A0 (en)	2006-10-05	Modulators of muscarinic receptors
GB0306575D0 (en)	2003-04-30	Modulators
IL173337A0 (en)	2006-06-11	Receptor
IL172921A0 (en)	2006-06-11	Cck-1 receptor modulators
SI1697371T1 (sl)	2007-10-31	Azabiciklični heterocikli kot modulatorji kanabinoidnega receptorja
SI1697370T1 (sl)	2007-10-31	Azabiciklični heterocikli kot modulatorji kanabinoidnega receptorja
GB0321998D0 (en)	2003-10-22	Receptor
ZA200606563B (en)	2008-10-29	3-Substituted 1,5-diphenylpyrazole derivatives useful as CB1 Modulators
IL173334A0 (en)	2006-06-11	Thiazole derivatives as cannabinoid receptor modulators
GB0307100D0 (en)	2003-04-30	Receptor
GB0329104D0 (en)	2004-01-21	Receptor
HK1084298A (zh)	2006-07-28	受体
GB0304064D0 (en)	2003-03-26	Receptors
GB0316354D0 (en)	2003-08-13	Receptors